8-K: Ligand Pharmaceuticals Reports Strong Q2 2024 Results Driven by Royalty and Milestone Payments

Ligand Pharmaceuticals announced a strong second quarter in 2024, with significant revenue growth driven by increased royalties and milestone payments.

Summary

• Ligand Pharmaceuticals reported total revenues and other income of $41.5 million for the second quarter of 2024, a significant increase from $26.4 million in the same period of 2023.
• The increase was primarily due to higher royalty revenue, which reached $23.2 million, up from $20.9 million in the prior year, and milestone payments from the approval of key programs.
• Captisol sales also increased to $7.5 million, compared to $5.2 million in the second quarter of 2023.
• Contract revenue and other income surged to $10.9 million, up from $0.2 million, driven by milestone payments for Ohtuvayre, CAPVAXIVE, and FILSPARI.
• GAAP net loss from continuing operations was $51.9 million, or $2.88 per share, compared to a net income of $2.3 million, or $0.13 per diluted share, in the same period of 2023, primarily due to non-cash losses from investments.
• Adjusted net income from continuing operations was $25.8 million, or $1.40 per diluted share, compared to $25.1 million, or $1.42 per diluted share, in the second quarter of 2023.
• Core adjusted net income, excluding gains from Viking Therapeutics stock sales in 2023, increased significantly to $25.8 million from $11.7 million in the prior year.
• For the six months ended June 30, 2024, total revenues and other income were $72.5 million, compared to $70.3 million in 2023.
• The company reaffirmed its 2024 financial guidance, expecting royalties between $100 million and $105 million, Captisol sales between $25 million and $27 million, and contract revenue between $15 million and $25 million.
• Ligand expects core adjusted earnings per diluted share to range from approximately $5.00 to $5.50 for 2024.

Sentiment

Score: 8

Explanation: The document presents a strong financial performance with significant revenue growth and expansion of the royalty portfolio. While there are some non-cash losses from investments, the overall tone is positive, with reaffirmed financial guidance and strategic acquisitions.

Positives

• Ligand experienced a substantial increase in total revenue and other income in the second quarter of 2024.
• The company's royalty revenue saw a notable increase, driven by sales of key products like FILSPARI and KYPROLIS.
• Captisol sales increased due to the timing of customer orders.
• Ligand secured significant milestone payments from the FDA approvals of Ohtuvayre and CAPVAXIVE, and the European Commission's approval of FILSPARI.
• The company added four new commercial-stage programs in the first half of the year, expanding its portfolio.
• Ligand's royalty portfolio has doubled since the beginning of 2023, now including 12 major commercial-stage programs.
• Ligand successfully expanded its credit facility with Citibank, increasing its financial flexibility.
• The acquisition of APEIRON Biologics adds a commercial-stage oncology product to Ligand's portfolio.
• Ligand reaffirmed its 2024 financial guidance, indicating confidence in future performance.
• Core adjusted net income increased significantly, driven by a 58% increase in revenue.

Negatives

• Ligand reported a GAAP net loss from continuing operations of $51.9 million for the second quarter of 2024, primarily due to non-cash losses from investments.
• The company experienced a $13.8 million non-cash unrealized loss from short-term investments associated with Viking Therapeutics stock.
• There was a $26.5 million decrease in the carrying value of investments, primarily related to Takeda's soticlestat.
• Ligand's investment in Primrose Bio decreased by $33.8 million due to a financing round at a lower valuation.
• General and administrative expenses increased due to higher stock-based compensation and costs associated with incubating the Pelthos business.
• GAAP net income from continuing operations for the six months ended June 30, 2024 decreased compared to the same period in 2023.

Risks

• Ligand relies on collaborative partners for revenue, and may not receive expected payments.
• The company may not receive expected revenue from Captisol material sales.
• Ligand and its partners may not be able to successfully advance products or receive regulatory approval.
• There is a risk that the market for developed products may be smaller than estimated.
• Ligand faces competition in acquiring royalties and locating suitable royalties to acquire.
• The company is dependent on a single source supplier for Captisol, which could cause delays.
• Ligand's partners may change their development focus or not execute on sales and marketing plans.
• Products may not be safe, efficacious, or perform as expected.
• Intellectual property may be challenged or invalidated.
• Partners may terminate agreements or development of products.
• Clinical trials may experience delays or issues.
• Integrating acquisitions may present challenges and costs.
• Ligand may not be able to successfully commercialize ZELSUVMI.
• Restrictions under the credit agreement may limit business flexibility.
• Changes in economic conditions or litigation could have a material adverse effect on the company.

Future Outlook

Ligand reaffirmed its 2024 financial guidance, expecting royalties to range from $100 million to $105 million, Captisol sales to range from $25 million to $27 million, and contract revenue to range from $15 million to $25 million, with core adjusted earnings per diluted share expected to range from approximately $5.00 to $5.50.

Management Comments

• We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December, said Todd Davis, CEO of Ligand.
• These developments underscore our commitment to expand our royalty portfolio, which now includes 12 major commercial-stage programs, double the number of programs we had at the beginning of 2023.

Industry Context

This announcement highlights Ligand's successful business model of acquiring and developing royalty streams from various pharmaceutical products. The company's focus on late-stage drug development and partnerships with major pharmaceutical companies positions it well within the biotech industry. The acquisition of APEIRON Biologics and the expansion of the credit facility further demonstrate Ligand's strategic growth initiatives.

Comparison to Industry Standards

• Ligand's royalty revenue growth is driven by products like Amgen's KYPROLIS and Travere Therapeutics' FILSPARI, which are established players in their respective markets. This is comparable to other royalty-focused biotech companies that rely on the success of their partners' products.
• The increase in Captisol sales is consistent with the growing demand for drug formulation technologies, similar to other companies in the pharmaceutical ingredient space.
• The milestone payments received by Ligand are typical for biotech companies that license their technologies or products to larger pharmaceutical firms. These payments are often tied to regulatory approvals and commercial launches, which are standard industry practices.
• The non-cash losses from investments, particularly in Viking Therapeutics and Takeda, are not uncommon in the biotech sector, where valuations can fluctuate significantly based on clinical trial results and market sentiment. This is similar to other companies with equity investments in publicly traded biotech firms.
• Ligand's adjusted net income performance is a key metric for investors, and its growth is a positive sign compared to other companies in the biotech space that may be struggling with profitability.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and profitability, as well as the expansion of the royalty portfolio.
• Employees may see increased job security and potential for growth due to the company's positive performance.
• Customers of Ligand's partners will have access to new and improved therapies.
• Suppliers of Captisol may see increased demand for their products.
• Creditors will have increased confidence in Ligand's ability to meet its financial obligations.

Next Steps

• Ligand will continue to advance its portfolio of partnered programs.
• The company will focus on the commercial launch of Ohtuvayre by Verona Pharma and ZELSUVMI by Pelthos Therapeutics.
• Ligand plans to continue discussions with the FDA regarding the development of various partnered products.
• Viking plans to schedule an end of Phase 2 meeting with the FDA in the fourth quarter of 2024.

Key Dates

Keywords

Ligand Pharmaceuticals, Royalty Revenue, Milestone Payments, Captisol, Biopharmaceutical, Drug Development, Commercial-Stage Programs, FDA Approval, Financial Results, APEIRON Biologics, QARZIBA, Ohtuvayre, CAPVAXIVE, FILSPARI, Viking Therapeutics, Primrose Bio